Diabetic macular edema is one of the leading causes of vision loss among workers in the US. Several studies looked at over 37,000 Hispanic and non-Hispanic whites with DME and visual impairment in the US in 2010. Data from the RISE, RIDE, and DRCR Network trials show that treatment with 0.3 mg of ranibizumab every 4 weeks for 2 years reduced the number of individuals with impairment by 45%, and reduced the number of individuals with legal blindness by 75%. Read the full report here.
![Ranibizumab Drastically Reduces Cases of Visual Impairment and Legal Blindness from DME](http://www.cmdconsults.com/wp-content/uploads/image-125x125.jpg)
Sorry, comments are closed for this post.